Cargando…

Heavy+light chain monitoring correlates with clinical outcome in multiple myeloma patients

Novel anti-myeloma agents have improved patient response rates, which are historically based on reductions of the M-protein. These methods can be inaccurate for quantifying M-proteins at low concentrations. We compared the consistency and clinical impact of response assignment by electrophoretic and...

Descripción completa

Detalles Bibliográficos
Autores principales:	Michallet, M, Chapuis-Cellier, C, Dejoie, T, Lombard, C, Caillon, H, Sobh, M, Moreau, P, Attal, M, Avet-Loiseau, H
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2018
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5808078/ https://www.ncbi.nlm.nih.gov/pubmed/28663581 http://dx.doi.org/10.1038/leu.2017.209

Ejemplares similares

Responses in multiple myeloma should be assigned according to serum, not urine, free light chain measurements
por: Dejoie, Thomas, et al.
Publicado: (2018)

Difficulties in immunofixation analysis: a concordance study on the IFM 2007-02 trial
por: Caillon, H, et al.
Publicado: (2013)

Prognostic utility of intact immunoglobulin Ig′κ/Ig′λ ratios in multiple myeloma patients
por: Bradwell, A, et al.
Publicado: (2013)

Gamma heavy chain disease associated with rheumatoid arthritis: a case report
por: Danic, Gwenvaël, et al.
Publicado: (2021)

Dynamic monitoring of myeloma minimal residual disease with targeted mass spectrometry
por: Noori, Somayya, et al.
Publicado: (2023)

Expressed fusion gene landscape and its impact in multiple myeloma
por: Cleynen, A., et al.
Publicado: (2017)

Deciphering the chronology of copy number alterations in Multiple Myeloma
por: Aktas Samur, Anil, et al.
Publicado: (2019)

All-oral triplet combination of ixazomib, lenalidomide, and dexamethasone in newly diagnosed transplant-eligible multiple myeloma patients: final results of the phase II IFM 2013-06 study
por: Touzeau, Cyrille, et al.
Publicado: (2022)

Immunoglobulin heavy/light chain ratios improve paraprotein detection and monitoring, identify residual disease and correlate with survival in multiple myeloma patients
por: Ludwig, H, et al.
Publicado: (2013)

Immunoglobulin heavy/light chain ratios improve paraprotein detection and monitoring, identify residual disease and correlate with survival in multiple myeloma patients
por: Ludwig, H, et al.
Publicado: (2013)

Logic programming reveals alteration of key transcription factors in multiple myeloma
por: Miannay, Bertrand, et al.
Publicado: (2017)

DNA hydroxymethylation is associated with disease severity and persists at enhancers of oncogenic regions in multiple myeloma
por: Alberge, Jean-Baptiste, et al.
Publicado: (2020)

Randall-Type Monoclonal IgE Kappa Light-Heavy Chain Deposition Disease
por: Isnard, Pierre, et al.
Publicado: (2023)

INDEPENDENT SYNTHESIS OF LIGHT AND HEAVY CHAINS : Quantitation of Light-Chain Production by Mouse Myeloma Variants
por: Laskov, Reuven, et al.
Publicado: (1974)

Immunoglobulin heavy/light chain analysis enhances the detection of residual disease and monitoring of multiple myeloma patients
por: Batinić, Josip, et al.
Publicado: (2015)

Front-line therapies for elderly patients with transplant-ineligible multiple myeloma and high-risk cytogenetics in the era of novel agents
por: Avet-Loiseau, Herve, et al.
Publicado: (2018)

B04 IMPLEMENTING M-PROTEIN DIAGNOSTICS IN MULTIPLE MYELOMA PATIENTS USING ULTRA-SENSITIVE TARGETED MASS SPECTROMETRY DATA AND AN OFF-THE-SHELF CALIBRATOR
por: Wijnands, C., et al.
Publicado: (2023)

The Current Role of the Heavy/Light Chain Assay in the Diagnosis, Prognosis and Monitoring of Multiple Myeloma: An Evidence-Based Approach
por: Ríos-Tamayo, Rafael, et al.
Publicado: (2021)

Optimizing therapy for del(17p) multiple myeloma
por: Avet-Loiseau, Hervé, et al.
Publicado: (2017)

Multiple Myeloma: Heterogeneous in Every Way
por: Schavgoulidze, Anaïs, et al.
Publicado: (2021)

Analysis of a Compartmental Model of Endogenous Immunoglobulin G Metabolism with Application to Multiple Myeloma
por: Kendrick, Felicity, et al.
Publicado: (2017)

Involved/uninvolved heavy/light chain index can predict progression in transplanted multiple myeloma patients
por: Espiño, M, et al.
Publicado: (2017)

P10 AN ULTRA-SENSITIVE METHOD FOR SEQUENCING AND MONITORING OF M-PROTEIN IN PERIPHERAL BLOOD (M-INSIGHT)
por: Bonifay, V., et al.
Publicado: (2023)

The clinical utility of serum free light chain and heavy/light chain assays in monitoring disease activity in patients with IgG myeloma after achieving a deep response
por: Shimizu, Kazuyuki, et al.
Publicado: (2017)

Follow-up of IgD-κ multiple myeloma by monitoring free light chains and total heavy chain IgD: A case report
por: De Santis, Elena, et al.
Publicado: (2016)

Long Intergenic Non-Coding RNAs have an Independent Impact on Survival in Multiple Myeloma
por: Samur, Mehmet Kemal, et al.
Publicado: (2018)

Risk and Response-Adapted Treatment in Multiple Myeloma
por: Cazaubiel, Titouan, et al.
Publicado: (2020)

RECOMBINATION OF HEAVY AND LIGHT CHAINS OF HUMAN γA-MYELOMA PROTEINS: FORMATION OF HYBRID MOLECULES AND CONFIGURATIONAL SPECIFICITY
por: Prendergast, Robert A., et al.
Publicado: (1966)

Functional Comparison between Healthy and Multiple Myeloma Adipose Stromal Cells
por: Espagnolle, Nicolas, et al.
Publicado: (2020)

Prognostic utility of serum free light chain ratios and heavy-light chain ratios in multiple myeloma in three PETHEMA/GEM phase III clinical trials
por: Lopez-Anglada, Lucia, et al.
Publicado: (2018)

Idiotypes of inulin-binding myeloma proteins localized to variable region light and heavy chains: genetic significance
Publicado: (1977)

Laboratory and Clinical Settings of Heavy/Light Chain (HLC) Assays in the Management of Monoclonal Gammopathies and Multiple Myeloma
por: Napodano, Cecilia, et al.
Publicado: (2023)

The shaping and functional consequences of the dosage effect landscape in multiple myeloma
por: Samur, Mehmet K, et al.
Publicado: (2013)

Fibrillary inclusions in light chain proximal tubulopathy associated with myeloma
por: Neild, G. H., et al.
Publicado: (2012)

Light Chain Myeloma Precipitating Cryoglobulinemic Vasculitis
por: Saeed, Bilal, et al.
Publicado: (2023)

Light chain myeloma and detection of free light chains in serum and urine of dogs and cats
por: Harris, Robert Adam, et al.
Publicado: (2021)

L’hyponatrémie semble être un facteur prédictif d’évolution défavorable dans l’infection COVID-19
por: Letellier, T., et al.
Publicado: (2020)

Abnormal heavy/light chain ratio after treatment is associated with shorter survival in patients with IgA myeloma
por: Suehara, Yasuhito, et al.
Publicado: (2017)

In-depth analysis of alternative splicing landscape in multiple myeloma and potential role of dysregulated splicing factors
por: Aktas Samur, Anil, et al.
Publicado: (2022)

Heavy-Chain Diseases and Myeloma-Associated Fanconi Syndrome: an Update
por: Ria, Roberto, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_hcueglhj6nev5oc088146dmnlr